biotx.ai Inc
- Biotech or pharma, therapeutic R&D
Causal mapping of the genome: Unveiling the genes that cause or influence biological effects, traits, or diseases
Our vision is to disrupt the high-risk biotech business model through a more predictable, data-driven approach. Through causal mapping of the genome, we elucidate the underlying biological mechanisms of diseases and enable robust prediction of clinical trial outcomes.
By curating a comprehensive catalog based on 9,539 Genome-wide association study (GWAS) datasets including 22,376,782 cases across 3,303 diseases, biotx.ai tested all 23,280 genes and more than 10,000 biomarkers for each disease using Mendelian randomization (MR) or colocalization. The platform leverages advanced machine learning to identify clusters, pinpointing the essential causal relationships of drug targets. This process connects drug targets directly to disease biology, uncovering novel candidates with verified causal links to various health conditions.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}